Medical, psychosocial, and health-related quality of life issues in breast cancer survivors

Oncology: An Evidence-Based Approach

Volumn , Issue , 2006, Pages 1846-1868

  Lemieux, Julie ^a   Bordeleau, Louise J ^a   Goodwin, Pamela J ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892317025     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/0-387-31056-8_106     Document Type: Chapter

References (150)

1. http://survivorship.cancer.gov.
2. Gerber LH. A review of measures of lymphedema. Cancer (Phila) 1998;83:2803-2804.
3. Erickson VS, Pearson ML, Ganz PA, Adams J, Kahn KL. Arm edema in breast cancer patients. J Natl Cancer Inst 2001;93: 96-111.
4. Schrenk P, Rieger R, Shamiyeh A, Wayand W. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer (Phila) 2000;88:608-614.
5. Gerber L, Lampert M, Wood C, et al. Comparison of pain, motion, and edema after modified radical mastectomy vs. local excision with axillary dissection and radiation. Breast Cancer Res Treat 1992;21:139-145.
6. Werner RS, McCormick B, Petrek J, et al. Arm edema in conservatively managed breast cancer: obesity is a major predictive factor. Radiology 1991;180:177-184.
7. Tasmuth T, von Smitten K, Kalso E. Pain and other symptoms during the first year after radical and conservative surgery for breast cancer. Br J Cancer 1996;74:2024-2031.
8. Paci E, Cariddi A, Barchielli A, et al. Long-term sequelae of breast cancer surgery. Tumori 1996;82:321-324.
9. Yeoh EK, Denham JW, Davies SA, Spittle MF. Primary breast cancer. Complications of axillary management. Acta Radiol Oncol 1986;25:105-108.
10. Kiel KD, Rademacker AW. Early-stage breast cancer: arm edema after wide excision and breast irradiation. Radiology 1996;198: 279-283.
11. Keramopoulos A, Tsionou C, Minaretzis D, Michalas S, Aravantinos D. Arm morbidity following treatment of breast cancer with total axillary dissection: a multivariated approach. Oncology 1993;50:445-449.
12. Liljegren G, Holmberg L. Arm morbidity after sector resection and axillary dissection with or without postoperative radiotherapy in breast cancer stage I. Results from a randomised trial. Uppsala-Orebro Breast Cancer Study Group. Eur J Cancer 1997; 33:193-199.
13. Senofsky GM, Moffat FL Jr, Davis K, et al. Total axillary lymphadenectomy in the management of breast cancer. Arch Surg 1991;126:1336-1341; discussion 1341-1342.
14. Kissin MW, Querci della Rovere G, Easton D, Westbury G. Risk of lymphoedema following the treatment of breast cancer. Br J Surg 1986;73:580-584.
15. Borup Christensen S, Lundgren E. Sequelae of axillary dissection vs. axillary sampling with or without irradiation for breast cancer. A randomized trial. Acta Chir Scand 1989;155:515-519.
16. Lash TL, Silliman RA. Patient characteristics and treatments associated with a decline in upper-body function following breast cancer therapy. J Clin Epidemiol 2000;53:615-622.
17. Silliman RA, Prout MN, Field T, Kalish SC, Colton T. Risk factors for a decline in upper body function following treatment for early stage breast cancer. Breast Cancer Res Treat 1999; 54:25-30.
18. Segerstrom K, Bjerle P, Nystrom A. Importance of time in assessing arm and hand function after treatment of breast cancer. Scand J Plast Reconstr Surg Hand Surg 1991;25:241-244.
19. Lin PP, Allison DC, Wainstock J, et al. Impact of axillary lymph node dissection on the therapy of breast cancer patients. J Clin Oncol 1993;11:1536-1544.
20. Passik SD, McDonald MV. Psychosocial aspects of upper extremity lymphedema in women treated for breast carcinoma. Cancer (Phila) 1998;83:2817-2820.
21. Woods M, Tobin M, Mortimer P. The psychosocial morbidity of breast cancer patients with lymphoedema. Cancer Nurs 1995;18:467-471.
22. Tobin MB, Lacey HJ, Meyer L, Mortimer PS. The psychological morbidity of breast cancer-related arm swelling. Psychological morbidity of lymphoedema. Cancer (Phila) 1993;72:3248-3252.
23. Maunsell E, Brisson J, Deschenes L. Arm problems and psychological distress after surgery for breast cancer. Can J Surg 1993; 36:315-320.
24. Harris PF, Remington PL, Trentham-Dietz A, Allen CI, Newcomb PA. Prevalence and treatment of menopausal symptoms among breast cancer survivors. J Pain Symptom Manag 2002;23:501-509.
25. Ganz PA. Menopause and breast cancer: symptoms, late effects, and their management. Semin Oncol 2001;28:274-283.
26. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999;17:2365-2370.
27. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996;14:1718-1729.
28. Bachmann GA. Vasomotor flushes in menopausal women. Am J Obstet Gynecol 1999;180:S312-S316.
29. Schwingl PJ, Hulka BS, Harlow SD. Risk factors for menopausal hot flashes. Obstet Gynecol 1994;84:29-34.
30. Theriault RL, Sellin RV. Estrogen-replacement therapy in younger women with breast cancer. J Natl Cancer Inst Monogr 1994;16:149-152.
31. Mortimer JE. Hormone replacement therapy and beyond. The clinical challenge of menopausal symptoms in breast cancer survivors. Geriatrics 2002;57:25-31.
32. Carpenter JS, Johnson D, Wagner L, Andrykowski M. Hot flashes and related outcomes in breast cancer survivors and matched comparison women. Oncol Nurs Forum 2002;29: E16-E25.
33. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results. From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
34. Pritchard KI, Khan H, Levine M. Clinical practice guidelines for the care and treatment of breast cancer: 14. The role of hormone replacement therapy in women with a previous diagnosis of breast cancer. Can Med Assoc J 2002;166:1017-1022.
35. Marsden J. Hormone-replacement therapy and breast cancer. Lancet Oncol 2002;3:303-311.
36. DiSaia PJ, Grosen EA, Kurosaki T, Gildea M, Cowan B, Anton- Culver H. Hormone replacement therapy in breast cancer survivors: a cohort study. Am J Obstet Gynecol 1996;174: 1494-1498.
37. Decker D, Cox T, Burdakin J. Hormone replacement therapy (HRT) in breast cancer survivors. Proc Am Soc Clin Oncol 1996;15:209.
38. Bluming AZ, Waisman JR, Dosik GM. Hormone replacement therapy (HRT) in women with previously treated breast cancer, update IV. Proc Am Soc Clin Oncol 1998;17:496.
39. Powles TJ, Hickish T, Casey S, O'Brien M. Hormone replacement after breast cancer. Lancet 1993;342:60-61.
40. Wile AG, Opfell RW, Margileth DA. Hormone replacement therapy does not affect breast cancer outcome. Proc Am Soc Clin Oncol 1991;10:58.
41. Wile AG, Opfell RW, Margileth DA. Hormone replacement therapy in previously treated breast cancer patients. Am J Surg 1993;165:372-375.
42. Eden JA, Wren BG, Dew J. Hormone replacement therapy after breast cancer. Educational book. Alexandria (VA): American Society of Clinical Oncology, 1996:187-189.
43. O'Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE, Weiss NS. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 2001;93:754-762.
44. Vassilopoulou-Sellin R, Asmar L, Hortobagyi GN, et al. Estrogen replacement therapy after localized breast cancer: clinical outcome of 319 women followed prospectively. J Clin Oncol 1999;17:1482-1487.
45. Ganz PA, Greendale GA, Kahn B, O'Leary JF, Desmond KA. Are older breast carcinoma survivors willing to take hormone replacement therapy? Cancer (Phila) 1999;86:814-820.
46. Biglia N, Cozzarella M, Cacciari F, et al. Menopause after breast cancer: a survey on breast cancer survivors. Maturitas 2003;45:29-38.
47. Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer-is it safe?): a randomised comparison: trial stopped. Lancet 2004;363:453-455.
48. Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 6: Executive summary and consensus statement. Proceedings of a conference held at Boar's Head Inn, Charlottesville, Virginia, September 21-23, 1997. Oncology (Huntingt) 1999;13:859-861, 865-866, 871-872 passim.
49. Kronenberg F. Hot flashes: epidemiology and physiology. Ann N Y Acad Sci 1990;592:52-86; discussion 123-133.
50. Notelovitz M, Lenihan JP, McDermott M, Kerber IJ, Nanavati N, Arce J. Initial 17beta-estradiol dose for treating vasomotor symptoms. Obstet Gynecol 2000;95:726-731.
51. Rabin DS, Cipparrone N, Linn ES, Moen M. Why menopausal women do not want to take hormone replacement therapy. Menopause 1999;6:61-67.
52. Stearns V, Hayes DF. Approach to menopausal symptoms in women with breast cancer. Curr Treat Options Oncol 2002;3: 179-190.
53. Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994;331: 347-352.
54. Bullock JL, Massey FM, Gambrell RD Jr. Use of medroxyprogesterone acetate to prevent menopausal symptoms. Obstet Gynecol 1975;46:165-168.
55. Morrison JC, Martin DC, Blair RA, et al. The use of medroxyprogesterone acetate for relief of climacteric symptoms. Am J Obstet Gynecol 1980;138:99-104.
56. Schiff I, Tulchinsky D, Cramer D, Ryan KJ. Oral medroxyprogesterone in the treatment of postmenopausal symptoms. JAMA 1980;244:1443-1445.
57. Bertelli G, Venturini M, Del Mastro L, et al. Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study. Ann Oncol 2002;13:883-888.
58. Guttuso T Jr, Kurlan R, McDermott MP, Kieburtz K. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2003;101: 337-345.
59. Naessen T, Rodriguez-Macias K, Lithell H. Serum lipid profile improved by ultra-low doses of 17 beta-estradiol in elderly women. J Clin Endocrinol Metab 2001;86:2757-2762.
60. Ganz PA, Greendale GA, Petersen L, Zibecchi L, Kahn B, Belin TR. Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. J Natl Cancer Inst 2000; 92:1054-1064.
61. Basil JB, Mutch DG. Role of hormone replacement therapy in cancer survivors. Clin Obstet Gynecol 2001;44:464-477.
62. Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001;19:3306-3311.
63. Recommended breast cancer surveillance guidelines. American Society of Clinical Oncology. J Clin Oncol 1997;15:2149-2156.
64. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991;265:1861-1867.
65. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987;316:1105-1110.
66. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995;273:199-208.
67. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280: 605-613.
68. Burstein HJ, Winer EP. Primary care for survivors of breast cancer. N Engl J Med 2000;343:1086-1094.
69. Surbone A, Petrek JA. Childbearing issues in breast carcinoma survivors. Cancer (Phila) 1997;79:1271-1278.
70. Collichio FA, Agnello R, Staltzer J. Pregnancy after breast cancer: from psychosocial issues through conception. Oncology (Huntingt) 1998;12:759-765, 769; discussion 770, 773-775.
71. Blakely LJ, Buzdar AU, Lozada JA, et al. Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer (Phila) 2004;100:465-469.
72. Kroman N, Jensen MB, Melbye M, Wohlfahrt J, Mouridsen HT. Should women be advised against pregnancy after breast-cancer treatment? Lancet 1997;350:319-322.
73. Velentgas P, Daling JR, Malone KE, et al. Pregnancy after breast carcinoma: outcomes and influence on mortality. Cancer (Phila) 1999;85:2424-2432.
74. Sutton R, Buzdar AU, Hortobagyi GN. Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. Cancer (Phila) 1990;65:847-850.
75. Mulvihill JJ, McKeen EA, Rosner F, Zarrabi MH. Pregnancy outcome in cancer patients. Experience in a large cooperative group. Cancer (Phila) 1987;60:1143-1150.
76. Higgins S, Haffty BG. Pregnancy and lactation after breastconserving therapy for early stage breast cancer. Cancer (Phila) 1994;73:2175-2180.
77. Tralins AH. Lactation after conservative breast surgery combined with radiation therapy. Am J Clin Oncol 1995;18:40-43.
78. Moore HC, Foster RS Jr. Breast cancer and pregnancy. Semin Oncol 2000;27:646-653.
79. Rosner D, Yeh J. Breast cancer and related pregnancy: suggested management according to stages of the disease and gestational stages. J Med 2002;33:23-62.
80. Ganz PA, Coscarelli A, Fred C, Kahn B, Polinsky ML, Petersen L. Breast cancer survivors: psychosocial concerns and quality of life. Breast Cancer Res Treat 1996;38:183-199.
81. Bower JE, Ganz PA, Desmond KA, Rowland JH, Meyerowitz BE, Belin TR. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol 2000;18: 743-753.
82. Andrykowski MA, Curran SL, Lightner R. Off-treatment fatigue in breast cancer survivors: a controlled comparison. J Behav Med 1998;21:1-18.
83. Hochster H, Wasserheit C, Speyer J. Cardiotoxicity and cardioprotection during chemotherapy. Curr Opin Oncol 1995;7: 304-309.
84. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266:1672-1677.
85. Swain SM. Adult multicenter trials using dexrazoxane to protect against cardiac toxicity. Semin Oncol 1998;25:43-47.
86. Sparano JA. Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics. Semin Oncol 1999;3(suppl 9):14-19.
87. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344: 783-792.
88. Grunfeld E, Fitzpatrick R, Mant D, et al. Comparison of breast cancer patient satisfaction with follow-up in primary care versus specialist care: results from a randomized controlled trial. Br J Gen Pract 1999;49:705-710.
89. Zabora J, BrintzenhofeSzoc K, Curbow B, Hooker C, Piantadosi S. The prevalence of psychological distress by cancer site. Psycho-Oncology 2001;10:19-28.
90. Gallagher J, Parle M, Cairns D. Appraisal and psychological distress six months after diagnosis of breast cancer. Br J Health Psychol 2002;7:365-376.
91. Kissane DW, Clarke DM, Ikin J, et al. Psychological morbidity and quality of life in Australian women with early-stage breast cancer: a cross-sectional survey. Med J Aust 1998;169:192-196.
92. Aragona M, Muscatello MR, Mesiti M. Depressive mood disorders in patients with operable breast cancer. J Exp Clin Cancer Res 1997;16:111-118.
93. Halttunen A, Hietanen P, Jallinoja P, Lonnqvist J. Getting free of breast cancer. An eight-year perspective of the relapse-free patients. Acta Oncol 1992;31:307-310.
94. Fredette SL. Breast cancer survivors: concerns and coping. Cancer Nurs 1995;18:35-46.
95. Ferrans CE. Quality of life through the eyes of survivors of breast cancer. Oncol Nurs Forum 1994;21:1645-1651.
96. Wyatt G, Kurtz ME, Liken M. Breast cancer survivors: an exploration of quality of life issues. Cancer Nurs 1993;16:440-448.
97. Carter BJ. Long-term survivors of breast cancer. A qualitative descriptive study. Cancer Nurs 1993;16:354-361.
98. Matthews BA, Baker F, Hann DM, Denniston M, Smith TG. Health status and life satisfaction among breast cancer survivor peer support volunteers. Psycho-Oncology 2002;11:199-211.
99. Ganz PA, Desmond KA, Leedham B, Rowland JH, Meyerowitz BE, Belin TR. Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst 2002; 94:39-49.
100. Ganz PA, Rowland JH, Meyerowitz BE, Desmond KA. Impact of different adjuvant therapy strategies on quality of life in breast cancer survivors. Recent Results Cancer Res 1998;152:396-411.
101. Tomich PL, Helgeson VS. Five years later: a cross-sectional comparison of breast cancer survivors with healthy women. Psycho- Oncology 2002;11:154-169.
102. Mosconi P, Apolone G, Barni S, Secondino S, Sbanotto A, Filiberti A. Quality of life in breast and colon cancer long-term survivors: an assessment with the EORTC QLQ-C30 and SF-36 questionnaires. Tumori 2002;88:110-116.
103. Dorval M, Maunsell E, Deschenes L, Brisson J, Masse B. Longterm quality of life after breast cancer: comparison of 8-year survivors with population controls. J Clin Oncol 1998;16:487-494.
104. Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000;18:2695-2701.
105. Dow KH, Ferrell BR, Leigh S, Ly J, Gulasekaram P. An evaluation of the quality of life among long-term survivors of breast cancer. Breast Cancer Res Treat 1996;39:261-273.
106. Ganz PA, Rowland JH, Desmond K, Meyerowitz BE, Wyatt GE. Life after breast cancer: understanding women's health-related quality of life and sexual functioning. J Clin Oncol 1998;16: 501-514.
107. Kurtz ME, Wyatt G, Kurtz JC. Psychological and sexual wellbeing, philosophical/spiritual views, and health habits of longterm cancer survivors. Health Care Women Int 1995;16: 253-262.
108. Dorval M, Maunsell E, Taylor-Brown J, Kilpatrick M. Marital stability after breast cancer. J Natl Cancer Inst 1999;91:54-59.
109. Wieneke MH, Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology 1995;4:61-66.
110. Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer (Phila) 1999;85: 640-650.
111. van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998;90:210-218.
112. Schagen SB, Muller MJ, Boogerd W, et al. Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol 2002;13:1387-1397.
113. Ahles TA, Saykin AJ, Furstenberg CT, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002;20: 485-493.
114. Ferrell BR. Overview of breast cancer: quality of life. Oncology Patient Care 1993;3:7-8.
115. Wyatt G, Kurtz ME, Friedman LL, Given B, Given CW. Preliminary testing of the Long-Term Quality of Life (LTQL) instrument for female cancer survivors. J Nurs Meas 1996;4:153-170.
116. Maunsell E, Drolet M, Brisson J, Robert J, Deschenes L. Dietary change after breast cancer: extent, predictors, and relation with psychological distress. J Clin Oncol 2002;20:1017-1025.
117. Burstein HJ, Gelber S, Guadagnoli E, Weeks JC. Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 1999;340:1733-1739.
118. Lee MM, Lin SS, Wrensch MR, Adler SR, Eisenberg D. Alternative therapies used by women with breast cancer in four ethnic populations. J Natl Cancer Inst 2000;92:42-47.
119. Maunsell E, Brisson J, Deschenes L. Psychological distress after initial treatment for breast cancer: a comparison of partial and total mastectomy. J Clin Epidemiol 1989;42:765-771.
120. Vinokur AD, Threatt BA, Caplan RD, Zimmerman BL. Physical and psychosocial functioning and adjustment to breast cancer. Long-term follow-up of a screening population. Cancer (Phila) 1989;63:394-405.
121. Cimprich B, Ronis DL, Martinez-Ramos G. Age at diagnosis and quality of life in breast cancer survivors. Cancer Pract 2002;10: 85-93.
122. Ganz PA, Greendale GA, Petersen L, Kahn B, Bower JE. Breast cancer in younger women: reproductive and late health effects of treatment. J Clin Oncol 2003;21:4184-4193.
123. Ganz PA, Guadagnoli E, Landrum MB, Lash TL, Rakowski W, Silliman RA. Breast cancer in older women: quality of life and psychosocial adjustment in the 15 months after diagnosis. J Clin Oncol 2003;21:4027-4033.
124. Ashing-Giwa K, Ganz PA, Petersen L. Quality of life of African- American and white long term breast carcinoma survivors. Cancer (Phila) 1999;85:418-426.
125. Dorval M, Maunsell E, Deschenes L, Brisson J. Type of mastectomy and quality of life for long term breast carcinoma survivors. Cancer (Phila) 1998;83:2130-2138.
126. Ganz PA, Schag AC, Lee JJ, Polinsky ML, Tan SJ. Breast conservation versus mastectomy. Is there a difference in psychological adjustment or quality of life in the year after surgery? Cancer (Phila) 1992;69:1729-1738.
127. Janni W, Rjosk D, Dimpfl TH, et al. Quality of life influenced by primary surgical treatment for stage I-III breast cancer-longterm follow-up of a matched-pair analysis. Ann Surg Oncol 2001;8:542-548.
128. Omne-Ponten M, Holmberg L, Sjoden PO. Psychosocial adjustment among women with breast cancer stages I and II: six-year follow-up of consecutive patients. J Clin Oncol 1994;12: 1778-1782.
129. Curran D, van Dongen JP, Aaronson NK, et al. Quality of life of early-stage breast cancer patients treated with radical mastectomy or breast-conserving procedures: results of EORTC Trial 10801. The European Organization for Research and Treatment of Cancer (EORTC), Breast Cancer Co-operative Group (BCCG). Eur J Cancer 1998;34:307-314.
130. Schain W, Edwards BK, Gorrell CR, et al. Psychosocial and physical outcomes of primary breast cancer therapy: mastectomy vs excisional biopsy and irradiation. Breast Cancer Res Treat 1983;3:377-382.
131. Meyer L, Aspegren K. Long-term psychological sequelae of mastectomy and breast conserving treatment for breast cancer. Acta Oncol 1989;28:13-18.
132. Omne-Ponten M, Holmberg L, Bergstrom R, Sjoden PO, Burns T. Psychosocial adjustment among husbands of women treated for breast cancer; mastectomy vs. breast-conserving surgery. Eur J Cancer 1993;29A:1393-1397.
133. Rowland JH, Desmond KA, Meyerowitz BE, Belin TR, Wyatt GE, Ganz PA. Role of breast reconstructive surgery in physical and emotional outcomes among breast cancer survivors. J Natl Cancer Inst 2000;92:1422-1429.
134. Nissen MJ, Swenson KK, Ritz LJ, Farrell JB, Sladek ML, Lally RM. Quality of life after breast carcinoma surgery: a comparison of three surgical procedures. Cancer (Phila) 2001;91: 1238-1246.
135. Joly F, Espie M, Marty M, Heron JF, Henry-Amar M. Long-term quality of life in premenopausal women with node-negative localized breast cancer treated with or without adjuvant chemotherapy. Br J Cancer 2000;83:577-582.
136. Holzner B, Kemmler G, Kopp M, et al. Quality of life in breast cancer patients-not enough attention for long-term survivors? Psychosomatics 2001;42:117-123.
137. Kessler TA. Contextual variables, emotional state, and current and expected quality of life in breast cancer survivors. Oncol Nurs Forum 2002;29:1109-1116.
138. Satariano WA, Ragheb NE, Branch LG, Swanson GM. Difficulties in physical functioning reported by middle-aged and elderly women with breast cancer: a case-control comparison. J Gerontol 1990;45:M3-M11.
139. Sneeuw KC, Aaronson NK, Yarnold JR, et al. Cosmetic and functional outcomes of breast conserving treatment for early stage breast cancer. 2. Relationship with psychosocial functioning. Radiother Oncol 1992;25:160-166.
140. Lash TL, Silliman RA. Long-term follow-up of upper-body function among breast cancer survivors. Breast J 2002;8:28-33.
141. Guidozzi F. Estrogen replacement therapy in breast cancer survivors. Int J Gynaecol Obstet 1999;64:59-63.
142. Brewster WR, DiSaia PJ, Grosen EA, McGonigle KF, Kuykendall JL, Creasman WT. An experience with estrogen replacement therapy in breast cancer survivors. Int J Fertil Womens Med 1999;44:186-192.
143. Peters GN, Fodera T, Sabol J, Jones S, Euhus D. Estrogen replacement therapy after breast cancer: a 12-year follow-up. Ann Surg Oncol 2001;8:828-832.
144. Durna EM, Crowe SM, Leader LR, Eden JA. Quality of life of breast cancer survivors: the impact of hormonal replacement therapy. Climacteric 2002;5:266-276.
145. Ellman R, Thomas BA. Is psychological wellbeing impaired in long-term survivors of breast cancer? J Med Screen 1995;2: 5-9.
146. Saleeba AK, Weitzner MA, Meyers CA. Subclinical psychological distress in long-term survivors of breat cancer: a preliminary communication. J Psychosocial Oncol 1996;14:83-93.
147. Weitzner MA, Meyers CA, Stuebing KK, Saleeba AK. Relationship between quality of life and mood in long-term survivors of breast cancer treated with mastectomy. Support Care Cancer 1997;5:241-248.
148. Lee CO. Quality of life and breast cancer survivors. Psychosocial and treatment issues. Cancer Pract 1997;5:309-316.
149. Montazeri A, Jarvandi S, Haghighat S, et al. Anxiety and depression in breast cancer patients before and after participation in a cancer support group. Patient Educ Couns 2001;45:195-198.
150. Mock V. Body image in women treated for breast cancer.NursRes1993;42:153- 157.